MarketPeel
Insider Trading Intelligence
ES

Evert B. Schimmelpennink

IBIO
DIRECTOR · IBIO, INC. · CIK 0001713795
FILING MIX · LIFETIME89%/11%
BUYS
16
SELLS
2
TOTAL VALUE
$302.6K
COMPANIES
3
ACTIVE SINCE
Jun 2021
HOLDINGS NOW
109,789
AVG SELL PX
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Evert B. Schimmelpennink, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+15.12%+3.43%+11.69%+11.69%
14d1+100.00%+7.98%+7.16%+0.82%+0.82%
30d1+100.00%+16.19%+12.79%+3.40%+3.40%
60d1+0.00%-10.12%
90d1+0.00%-31.55%+15.64%-47.18%-47.18%
180d1(1 pending)
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
IBIO · 13,500 shares · as of Nov 20, 2025
027,25054,50081,750109,0002022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 16 buys / 2 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,00019,000Jun 26, 2026Jun 26, 2026View →
LENZ
LENZ THERAPEUTICS, INC.
PURCHASE
President, CEO and Secretary
28,089$8.95$251.4K77,289Mar 27, 2026Mar 30, 2026View →
LENZ
LENZ THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
358,100358,100Jan 2, 2026Jan 6, 2026View →
IBIO
IBIO, INC.
PURCHASEGRANT
Stock grant
13,50013,500Nov 20, 2025Nov 24, 2025View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,75014,750Jun 26, 2025Jun 26, 2025View →
LENZ
LENZ THERAPEUTICS, INC.
PURCHASE
President, CEO and Secretary
4,200$1.04$4.4K49,200Mar 7, 2025Mar 7, 2025View →
LENZ
LENZ THERAPEUTICS, INC.
SALE
President, CEO and Secretary
4,200337,906Mar 7, 2025Mar 7, 2025View →
LENZ
LENZ THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
279,100279,100Jan 9, 2025Jan 13, 2025View →
IBIO
IBIO, INC.
PURCHASEGRANT
Stock grant
18,90018,900Nov 21, 2024Nov 25, 2024View →
LENZ
LENZ THERAPEUTICS, INC.
PURCHASE
President, CEO and Secretary
45,000$1.04$46.8K45,000Jul 22, 2024Jul 23, 2024View →
LENZ
LENZ THERAPEUTICS, INC.
SALE
President, CEO and Secretary
45,000342,106Jul 22, 2024Jul 23, 2024View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
29,50029,500May 24, 2024May 29, 2024View →
LENZ
LENZ THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
475,000475,000Mar 21, 2024Mar 25, 2024View →
LENZ
LENZ THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
387,106387,106Mar 21, 2024Mar 25, 2024View →
LENZ
LENZ THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
82,72382,723Mar 21, 2024Mar 25, 2024View →
LENZ
LENZ THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
315,864315,864Mar 21, 2024Mar 25, 2024View →
IBIO
IBIO, INC.
PURCHASEGRANT
Stock grant
109,000109,000Dec 9, 2021Dec 13, 2021View →
IBIO
IBIO, INC.
PURCHASEGRANT
Stock grant
100,000100,000Jun 7, 2021Jun 9, 2021View →
Other insiders · IBIO
Loading peer insiders…
About this filer
CIK 0001713795
ROLE
Director
PRIMARY
IBIO
COMPANIES
3
ACTIVE SINCE
Jun 2021
MARKETPEEL · /INSIDER/0001713795DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback